Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT

IF 4.5 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2024-08-27 DOI:10.1038/s41409-024-02401-4

Urban Novak, Jarl E. Mooyaart, Michael Daskalakis, Christof Scheid, Ludovic Gabellier, Ibrahim Yakoub-Agha, Ron Ram, Edouard Forcade, Lucía López-Corral, Emma Nicholson, Eugenio Galli, Friedrich Stölzel, Wolfgang Bethge, Eva Maria Wagner-Drouet, Jorinde D. Hoogenboom, Stephan Mielke, Caroline Arber, Federico Simonetta, Christian Chabannon, Jürgen Kuball, Annalisa Ruggeri, Florent Malard

引用次数: 0

Abstract Image

查看原文本刊更多论文

欧洲对商用 CAR-T 细胞产品用于 R/R DLBCL 和 PMBCL 的选择：代表 EBMT 细胞疗法和免疫生物学工作组 (CTIWP) 进行的调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.